ADPT
HEALTHCAREAdaptive Biotechnologies Corp
AI Insight
What's Moving ADPT Today?
No stock-specific AI insight has been generated for ADPT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$9.96$20.76
$17.23
Fundamentals
Market Cap$2.8B
P/E Ratio—
EPS$-0.32
Dividend Yield—
Dividend / Share—
ROE-24.0%
Profit Margin-16.8%
Debt / Equity—
Trading
Volume2.3M
Avg Volume (10D)—
Shares Outstanding160.0M
ADPT News
32 articles- Adaptive Biotechnologies Corp - Issues $345 Million In 0% Convertible Senior Notes Due 2031 - SEC FilingTradingView·Jun 23, 2026
- Adaptive Biotechnologies (Nasdaq: ADPT) sells $345M 0% notes and repays OrbiMed dealStock Titan·Jun 23, 2026
- Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes OfferingYahoo Finance·Jun 17, 2026
- Adaptive Biotechnologies proposes $250M convertible notes, plans MRD/Immune Medicine separationTradingView·Jun 16, 2026
- [144] Adaptive Biotechnologies Corp SEC FilingStock Titan·Jun 16, 2026
- Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine BusinessesYahoo Finance·Jun 15, 2026
- Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes OfferingYahoo Finance·Jun 15, 2026
- What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors?The Motley Fool·Jun 14, 2026
- Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last?Yahoo Finance·Jun 12, 2026
- OpenFold Consortium Adds Eleven New Members as Momentum Builds for Open AI Infrastructure in Biology and Drug DiscoveryYahoo Finance·Jun 9, 2026
- [144] Adaptive Biotechnologies Corp SEC FilingStock Titan·Jun 4, 2026
- ADPT (NASDAQ: ADPT) affiliate notifies planned sale after option exerciseStock Titan·Jun 4, 2026
- How The Adaptive Biotechnologies (ADPT) Narrative Is Shifting Around A US$20 Fair Value AnchorYahoo Finance·Jun 4, 2026
- Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at ConferenceMarketbeat·Jun 3, 2026
- Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026Yahoo Finance·Jun 3, 2026
- At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and ResearchYahoo Finance·May 29, 2026
- Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 MillionMotley Fool·May 26, 2026
- Adaptive Biotechnologies to Participate in Upcoming Investor ConferencesYahoo Finance·May 21, 2026
- Adaptive Biotechnologies (ADPT) CFO tax-related share sale leaves 256,725 shares heldStock Titan·May 21, 2026
- Viking firms hold 18.8% of Adaptive Biotechnologies (NASDAQ: ADPT)Stock Titan·May 16, 2026
- Assessing Adaptive Biotechnologies (ADPT) Valuation After Strong MRD Growth And Raised Full Year GuidanceYahoo Finance·May 11, 2026
- Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesYahoo Finance·May 5, 2026
- Adaptive Biotechnologies Q1 Earnings Call HighlightsMarketbeat·May 5, 2026
- Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 5, 2026
- Adaptive Biotechnologies Reports First Quarter 2026 Financial ResultsYahoo Finance·May 5, 2026
- Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors.Motley Fool·May 4, 2026
- How The Investment Story For Adaptive Biotechnologies (ADPT) Is Shifting With New Street AssumptionsYahoo Finance·May 3, 2026
- Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It MeansMotley Fool·Apr 20, 2026
- Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares?The Motley Fool·Apr 18, 2026
- Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus OnThe Motley Fool·Apr 8, 2026
- Adaptive Biotech's President Trimmed Her Position. But what Remains is worth a lookThe Motley Fool·Mar 31, 2026
- Adaptive Biotech Insider Sale of 180,000 Shares Tied to Tax Event as Stock Jumps 70% in a YearThe Motley Fool·Mar 26, 2026
All 32 articles loaded
Price Data
Open$17.14
Previous Close$17.37
Day High$17.89
Day Low$17.13
52 Week High$20.76
52 Week Low$9.96
52-Week Range
$9.96$20.76
$17.23
Fundamentals
Market Cap$2.8B
P/E Ratio—
EPS$-0.32
Dividend Yield—
Dividend / Share—
ROE-24.0%
Profit Margin-16.8%
Debt / Equity—
Trading
Volume2.3M
Avg Volume (10D)—
Shares Outstanding160.0M
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.
HEALTHCAREDIAGNOSTICS & RESEARCH
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDIAGNOSTICS & RESEARCH
CIK—
Composite FIGI—
Share Class FIGI—